Skip to main content
NCBI home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 2005 Mar;97(3):329–333.

Relationship of C-reactive protein and bone mineral density in community-dwelling elderly females.

Kalpana Ganesan 1, Senait Teklehaimanot 1, The-Huy Tran 1, Merlyn Asuncion 1, Keith Norris 1
PMCID: PMC2568626  PMID: 15779496

Abstract

OBJECTIVE: Inflammatory cytokines have been shown to play an important role in bone remodeling. We hypothesized that higher levels of C-reactive protein (CRP) are associated with low bone mineral density (BMD) in elderly females. DESIGN: Secondary data analysis of the Third National Health and Nutrition Examination Survey. PARTICIPANTS: 2,807 females 65 years and older. RESULTS: CRP was associated with BMD in the bivariate sis (p<0.001) but not in the multivariate analysis (p=0.23) Age, ethnicity, body mass index (BMI), hormone replacement therapy (HRT) and immobility were independently associated with BMD. CONCLUSIONS: CRP may be useful in screening for osteoporosis among community-dwelling elderly females. However, CRP appears to act as a surrogate for other factorsdirectly associated with osteoporosis. Further studies are needed to validate these findings.

Full text

PDF
329

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baumann H., Gauldie J. The acute phase response. Immunol Today. 1994 Feb;15(2):74–80. doi: 10.1016/0167-5699(94)90137-6. [DOI] [PubMed] [Google Scholar]
  2. Bellido T., Jilka R. L., Boyce B. F., Girasole G., Broxmeyer H., Dalrymple S. A., Murray R., Manolagas S. C. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J Clin Invest. 1995 Jun;95(6):2886–2895. doi: 10.1172/JCI117995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Byrne D. J., Jagroop I. A., Montgomery H. E., Thomas M., Mikhailidis D. P., Milton N. G., Winder A. F. Lipoprotein (a) does not participate in the early acute phase response to training or extreme physical activity and is unlikely to enhance any associated immediate cardiovascular risk. J Clin Pathol. 2002 Apr;55(4):280–285. doi: 10.1136/jcp.55.4.280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cohn S. H., Abesamis C., Yasumura S., Aloia J. F., Zanzi I., Ellis K. J. Comparative skeletal mass and radial bone mineral content in black and white women. Metabolism. 1977 Feb;26(2):171–178. doi: 10.1016/0026-0495(77)90052-x. [DOI] [PubMed] [Google Scholar]
  5. Ershler W. B. Interleukin-6: a cytokine for gerontologists. J Am Geriatr Soc. 1993 Feb;41(2):176–181. doi: 10.1111/j.1532-5415.1993.tb02054.x. [DOI] [PubMed] [Google Scholar]
  6. Ferrari S. L., Ahn-Luong L., Garnero P., Humphries S. E., Greenspan S. L. Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. J Clin Endocrinol Metab. 2003 Jan;88(1):255–259. doi: 10.1210/jc.2002-020092. [DOI] [PubMed] [Google Scholar]
  7. Gough A., Sambrook P., Devlin J., Huissoon A., Njeh C., Robbins S., Nguyen T., Emery P. Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol. 1998 Jul;25(7):1282–1289. [PubMed] [Google Scholar]
  8. Hilbert D. M., Kopf M., Mock B. A., Köhler G., Rudikoff S. Interleukin 6 is essential for in vivo development of B lineage neoplasms. J Exp Med. 1995 Jul 1;182(1):243–248. doi: 10.1084/jem.182.1.243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hui S. L., Wiske P. S., Norton J. A., Johnston C. C., Jr A prospective study of change in bone mass with age in postmenopausal women. J Chronic Dis. 1982;35(9):715–725. doi: 10.1016/0021-9681(82)90095-9. [DOI] [PubMed] [Google Scholar]
  10. Jilka R. L., Hangoc G., Girasole G., Passeri G., Williams D. C., Abrams J. S., Boyce B., Broxmeyer H., Manolagas S. C. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science. 1992 Jul 3;257(5066):88–91. doi: 10.1126/science.1621100. [DOI] [PubMed] [Google Scholar]
  11. Kania D. M., Binkley N., Checovich M., Havighurst T., Schilling M., Ershler W. B. Elevated plasma levels of interleukin-6 in postmenopausal women do not correlate with bone density. J Am Geriatr Soc. 1995 Mar;43(3):236–239. doi: 10.1111/j.1532-5415.1995.tb07328.x. [DOI] [PubMed] [Google Scholar]
  12. Liel Y., Edwards J., Shary J., Spicer K. M., Gordon L., Bell N. H. The effects of race and body habitus on bone mineral density of the radius, hip, and spine in premenopausal women. J Clin Endocrinol Metab. 1988 Jun;66(6):1247–1250. doi: 10.1210/jcem-66-6-1247. [DOI] [PubMed] [Google Scholar]
  13. Lindsay R., Tohme J. F. Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol. 1990 Aug;76(2):290–295. [PubMed] [Google Scholar]
  14. Oelzner P., Franke S., Müller A., Hein G., Stein G. Relationship between soluble markers of immune activation and bone turnover in post-menopausal women with rheumatoid arthritis. Rheumatology (Oxford) 1999 Sep;38(9):841–847. doi: 10.1093/rheumatology/38.9.841. [DOI] [PubMed] [Google Scholar]
  15. Orwoll E. S., Bauer D. C., Vogt T. M., Fox K. M. Axial bone mass in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med. 1996 Jan 15;124(2):187–196. doi: 10.7326/0003-4819-124-2-199601150-00001. [DOI] [PubMed] [Google Scholar]
  16. Pradhan Aruna D., Manson JoAnn E., Rossouw Jacques E., Siscovick David S., Mouton Charles P., Rifai Nader, Wallace Robert B., Jackson Rebecca D., Pettinger Mary B., Ridker Paul M. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA. 2002 Aug 28;288(8):980–987. doi: 10.1001/jama.288.8.980. [DOI] [PubMed] [Google Scholar]
  17. Primatesta Paola, Falaschetti Emanuela, Poulter Neil R. Influence of hormone replacement therapy on C-reactive protein: population-based data. J Cardiovasc Risk. 2003 Feb;10(1):57–60. doi: 10.1097/01.hjr.0000050717.61003.d4. [DOI] [PubMed] [Google Scholar]
  18. Ray N. F., Chan J. K., Thamer M., Melton L. J., 3rd Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997 Jan;12(1):24–35. doi: 10.1359/jbmr.1997.12.1.24. [DOI] [PubMed] [Google Scholar]
  19. Riesmeier J. W., Willmitzer L., Frommer W. B. Evidence for an essential role of the sucrose transporter in phloem loading and assimilate partitioning. EMBO J. 1994 Jan 1;13(1):1–7. doi: 10.1002/j.1460-2075.1994.tb06229.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Rossouw Jacques E., Anderson Garnet L., Prentice Ross L., LaCroix Andrea Z., Kooperberg Charles, Stefanick Marcia L., Jackson Rebecca D., Beresford Shirley A. A., Howard Barbara V., Johnson Karen C. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002 Jul 17;288(3):321–333. doi: 10.1001/jama.288.3.321. [DOI] [PubMed] [Google Scholar]
  21. Scheidt-Nave C., Bismar H., Leidig-Bruckner G., Woitge H., Seibel M. J., Ziegler R., Pfeilschifter J. Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. J Clin Endocrinol Metab. 2001 May;86(5):2032–2042. doi: 10.1210/jcem.86.5.7445. [DOI] [PubMed] [Google Scholar]
  22. Schneider D. L., Barrett-Connor E. L., Morton D. J. Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study. JAMA. 1997 Feb 19;277(7):543–547. doi: 10.1001/jama.277.7.543. [DOI] [PubMed] [Google Scholar]
  23. Tamura T., Udagawa N., Takahashi N., Miyaura C., Tanaka S., Yamada Y., Koishihara Y., Ohsugi Y., Kumaki K., Taga T. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11924–11928. doi: 10.1073/pnas.90.24.11924. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Thompson D., Milford-Ward A., Whicher J. T. The value of acute phase protein measurements in clinical practice. Ann Clin Biochem. 1992 Mar;29(Pt 2):123–131. doi: 10.1177/000456329202900201. [DOI] [PubMed] [Google Scholar]
  25. Villareal D. T., Binder E. F., Williams D. B., Schechtman K. B., Yarasheski K. E., Kohrt W. M. Bone mineral density response to estrogen replacement in frail elderly women: a randomized controlled trial. JAMA. 2001 Aug 15;286(7):815–820. doi: 10.1001/jama.286.7.815. [DOI] [PubMed] [Google Scholar]
  26. Walsh B. W., Cox D. A., Sashegyi A., Dean R. A., Tracy R. P., Anderson P. W. Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. Am J Cardiol. 2001 Oct 1;88(7):825–828. doi: 10.1016/s0002-9149(01)01865-3. [DOI] [PubMed] [Google Scholar]
  27. Weinhold B., Rüther U. Interleukin-6-dependent and -independent regulation of the human C-reactive protein gene. Biochem J. 1997 Oct 15;327(Pt 2):425–429. doi: 10.1042/bj3270425. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Ylikorkala Olavi, Eviö Sirpa, Välimäki Matti, Tiitinen Aila. Effects of hormone therapy and alendronate on C-reactive protein, E-selectin, and sex hormone-binding globulin in osteoporotic women. Fertil Steril. 2003 Sep;80(3):541–545. doi: 10.1016/s0015-0282(03)00753-2. [DOI] [PubMed] [Google Scholar]
  29. van Baal W. M., Kenemans P., van der Mooren M. J., Kessel H., Emeis J. J., Stehouwer C. D. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women. Thromb Haemost. 1999 Jun;81(6):925–928. [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES